Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting
April 27th, 2008
GlaxoSmithKline (NYSE:GSK) confirmed it has received a warning letter from the US Food and Drug Administration (FDA) related to reporting requirements for approved medicines. The letter follows a routine FDA inspection of GSK's reporting processes conducted last year. The observations from the inspection primarily relate to omissions from periodic reports to the FDA regarding Avandia(R) (rosiglitazone maleate), such as the start and progress of clinical trials, and summaries of final data from some clinical trials. The FDA inspection also reviewed GSK's processes for reporting individual adverse events, which resulted in no inspection citations. The...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-27)
|
